Category: monoclonal
-
آنتی بادیهای ایمونوهیستوشیمیآنتی بادی CD43 کلون SPN/3388 برند Patho Sage
Specification:
It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% if T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be malignant lymphoma, especially a low grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.
Immunogen:
Recombinant full-length human SPN protein
Presentation:
Purified antibody from bioreactor concentrates by protein A/G. Prepared in 10mM PBS with 0.05% BSA and 0.05% Azide.
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی WT1 (Wilms Tumor) کلون WT49 برند Patho Sage
Specification:
The WT1 gene, identified as a tumor suppressor gene located at 11p13, is involved in the development of Wilms’ tumor. The WT1 gene encodes a transcription factor with four DNA-binding zinc fingers at the C terminus. In vitro studies showed that WT1 suppresses or activates a number of genes, including those for PDGF-A chain, EGF receptor, CSF-1, IGF-II, IGF-I receptor, RAR-α, c-myc, bcl-2 and WT1 itself. Immunohistochemically, WT1 is detected in the nucleus of tumor cells of Wilms’ tumor and mesothelioma; therefore, WT1 has traditionally been used as a diagnostic marker for these tumors. Recent reports showed that other types of cancers, such as ovarian serous cancers and rhabdomyosarcomas also express WT1.
Presentation:
Tissue culture supernatant containing 15mM sodium azide
-
آنتی بادیهای ایمونوهیستوشیمیآنتی بادی PR (Progesterone Receptor) کلون ZR4 برند Patho Sage
Specification:
The progesterone receptor (PgR) is an estrogen regulated protein. It has been proposed that expression of PgR determination indicates a responsive estrogen receptor (ER) pathway, and therefore, may predict likely response to endocrine therapy in human breast cancer. A number of studies have shown that PgR determination provides supplementary information to ER, both in predicting response to endocrine therapy and estimating survival. PgR has proved superior to ER as a prognostic indicator in some studies.
Immunogen:
Recombinant protein encoding human progesterone receptor 412-526 aa
Presentation:
Tissue culture supernatant with 0.2% BSA and 15mM sodium azide